<p>诺瓦瓦克斯（NASDAQ:NVAX - 获取免费报告）预计将在 2025 年 11 月 6 日星期四市场开盘前发布其 2025 年第三季度财报。分析师预计该公司将宣布每股收益为（$0.44），季度收入为 5563 万美元。投资者可以访问该公司即将发布的 2025 年第三季度财报页面，以获取关于定于 2025 年 11 月 6 日东部时间上午 8:30 的电话会议的最新详情。</p>
<ul>
<li>分析师认为这些股票的价值可能会翻倍</li>
</ul>
<p>诺瓦瓦克斯（NASDAQ:NVAX - 获取免费报告）最近一次发布季度财报是在 8 月 6 日星期三。这家生物制药公司报告季度每股收益为$0.62，超出市场共识预期的（$0.07）$0.69。诺瓦瓦克斯的股本回报率为负 142.33%，净利润率为 39.20%。该公司在本季度的收入为 2.3924 亿美元，而分析师的预期为 1.4919 亿美元。去年同期，该公司每股收益为$0.99。该公司的季度收入同比下降了 42.4%。分析师平均预计诺瓦瓦克斯在当前财政年度的每股收益为-$1，下一财政年度的每股收益为$0。</p>
<h2>诺瓦瓦克斯价格表现</h2>
<p>在周五的午盘交易中，NASDAQ:NVAX 的股票上涨了$0.03，达到了$8.46。该公司的交易量为 749,350 股，而其平均交易量为 6,281,517 股。该股票的市值为 13.7 亿美元，市盈率为 3.71，市盈增长比率为 0.12，贝塔值为 2.74。诺瓦瓦克斯的 12 个月低点为$5.01，12 个月高点为$11.55。该公司的债务与股本比率为 5.93，流动比率为 2.36，速动比率为 2.34。该公司的 50 日简单移动平均线为$8.37，200 日简单移动平均线为$7.50。</p>
<h2>对诺瓦瓦克斯的对冲基金看法</h2>
<ul>
<li>生物技术的牛市结束了吗？审视选举影响</li>
</ul>
<p>一些对冲基金和其他机构投资者最近对该股票的持仓进行了调整。Thrivent Financial for Lutherans 在第二季度购买了诺瓦瓦克斯的新股份，价值约为 132.1 万美元。怀俄明州购买了诺瓦瓦克斯的新股份，价值约为 52,000 美元。Headlands Technologies LLC 在第二季度购买了诺瓦瓦克斯的新股份，价值约为 90.3 万美元。Tower Research Capital LLC TRC 在第二季度将其在诺瓦瓦克斯的持股增加了 437.3%。Tower Research Capital LLC TRC 现在拥有诺瓦瓦克斯生物制药公司价值 23.5 万美元的 37,335 股股票，此前在上个季度又购买了 30,386 股。最后，E Fund Management Co. Ltd.在第二季度将其在诺瓦瓦克斯的持股增加了 9.0%。E Fund Management Co. Ltd.现在拥有诺瓦瓦克斯生物制药公司价值 17.8 万美元的 28,280 股股票，此前在上个季度又购买了 2,326 股。对冲基金和其他机构投资者持有该公司 53.04% 的股份。</p>
<h2>分析师设定新目标价</h2>
<p>几位研究分析师最近对该公司发表了评论。美国银行在 8 月 20 日的研究报告中重申了 “表现不佳” 的评级，并将诺瓦瓦克斯的目标价从$9.00 下调至$7.00。HC Wainwright 在 10 月 23 日的研究报告中将诺瓦瓦克斯的目标价从$10.00 上调至$11.00，并给予该股票 “买入” 评级。Cantor Fitzgerald 在 10 月 24 日的研究报告中开始覆盖诺瓦瓦克斯，设定了 “增持” 评级和$18.00 的目标价。最后，Weiss Ratings 在 10 月 8 日的报告中重申了诺瓦瓦克斯的 “卖出（d+）” 评级。四位分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，四位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为$11.33。</p>
<ul>
<li>Moderna 在第二季度财报后下跌，但能否因短期挤压而反弹？</li>
</ul>
<p><strong>查看我们关于 NVAX 的最新研究报告</strong></p>
<h2>关于诺瓦瓦克斯</h2>
<p>（获取免费报告）</p>
<p>诺瓦瓦克斯公司是一家生物技术公司，致力于通过发现、开发和商业化疫苗来改善健康，以保护人们免受严重传染病的侵害。它提供的疫苗平台结合了重组蛋白方法、纳米颗粒技术和其专利的 Matrix-M 佐剂，以增强免疫反应。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票而非诺瓦瓦克斯</li>
<li>复利及其在投资中的重要性</li>
<li>Comfort Systems 是击败 NVDA、AVGO 和 AMD 的 AI 数据中心股票</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>Cameco 的 800 亿美元美国核能交易改变一切</li>
<li>万亿美元市值的意义超越数字</li>
<li>NU 股票：美国银行许可证可能是下一个增长催化剂</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlZBWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在诺瓦瓦克斯吗？</h2>
<p>在你考虑诺瓦瓦克斯之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而诺瓦瓦克斯并不在名单上。</p>
<p>虽然诺瓦瓦克斯目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

诺瓦瓦克斯医药

<p>诺瓦瓦克斯医药（NASDAQ:NVAX）将于 11 月 6 日发布 2025 年第三季度财报，分析师预测每股亏损 0.44 美元，收入为 5563 万美元。该公司此前报告了 2025 年第二季度每股收益 0.62 美元，超出预期。诺瓦瓦克斯医药的股票目前交易价格为 8.46 美元，市值为 13.7 亿美元。分析师的评级不一，平均目标价格为 11.33 美元。机构投资者持有该公司 53.04% 的股份，显示出对公司的显著兴趣</p>

<p>Novavax (NASDAQ:NVAX - Get Free Report) is expected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $55.63 million for the quarter. Investors may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.</p>
<div class="lb-trans"><p>诺瓦瓦克斯（NASDAQ:NVAX - 获取免费报告）预计将在 2025 年 11 月 6 日星期四市场开盘前发布其 2025 年第三季度财报。分析师预计该公司将宣布每股收益为（$0.44），季度收入为 5563 万美元。投资者可以访问该公司即将发布的 2025 年第三季度财报页面，以获取关于定于 2025 年 11 月 6 日东部时间上午 8:30 的电话会议的最新详情。</p>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为这些股票的价值可能会翻倍</li>
</ul>
</div><p>Novavax (NASDAQ:NVAX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.69. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The firm had revenue of $239.24 million during the quarter, compared to analysts' expectations of $149.19 million. During the same quarter last year, the firm earned $0.99 earnings per share. The business's revenue for the quarter was down 42.4% on a year-over-year basis. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>诺瓦瓦克斯（NASDAQ:NVAX - 获取免费报告）最近一次发布季度财报是在 8 月 6 日星期三。这家生物制药公司报告季度每股收益为$0.62，超出市场共识预期的（$0.07）$0.69。诺瓦瓦克斯的股本回报率为负 142.33%，净利润率为 39.20%。该公司在本季度的收入为 2.3924 亿美元，而分析师的预期为 1.4919 亿美元。去年同期，该公司每股收益为$0.99。该公司的季度收入同比下降了 42.4%。分析师平均预计诺瓦瓦克斯在当前财政年度的每股收益为-$1，下一财政年度的每股收益为$0。</p>
</div><h2>Novavax Price Performance</h2>
<div class="lb-trans"><h2>诺瓦瓦克斯价格表现</h2>
</div><p>Shares of NASDAQ:NVAX traded up $0.03 during midday trading on Friday, hitting $8.46. The company had a trading volume of 749,350 shares, compared to its average volume of 6,281,517. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of 3.71, a price-to-earnings-growth ratio of 0.12 and a beta of 2.74. Novavax has a twelve month low of $5.01 and a twelve month high of $11.55. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34. The business's 50-day simple moving average is $8.37 and its 200-day simple moving average is $7.50.</p>
<div class="lb-trans"><p>在周五的午盘交易中，NASDAQ:NVAX 的股票上涨了$0.03，达到了$8.46。该公司的交易量为 749,350 股，而其平均交易量为 6,281,517 股。该股票的市值为 13.7 亿美元，市盈率为 3.71，市盈增长比率为 0.12，贝塔值为 2.74。诺瓦瓦克斯的 12 个月低点为$5.01，12 个月高点为$11.55。该公司的债务与股本比率为 5.93，流动比率为 2.36，速动比率为 2.34。该公司的 50 日简单移动平均线为$8.37，200 日简单移动平均线为$7.50。</p>
</div><h2>Hedge Funds Weigh In On Novavax</h2>
<div class="lb-trans"><h2>对诺瓦瓦克斯的对冲基金看法</h2>
</div><ul>
<li>Is Biotech’s Bull Run Over? Examining Election Impacts</li>
</ul>
<div class="lb-trans"><ul>
<li>生物技术的牛市结束了吗？审视选举影响</li>
</ul>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Thrivent Financial for Lutherans purchased a new stake in Novavax in the 2nd quarter valued at approximately $1,321,000. State of Wyoming purchased a new stake in Novavax in the 2nd quarter valued at approximately $52,000. Headlands Technologies LLC purchased a new stake in Novavax in the 2nd quarter valued at approximately $903,000. Tower Research Capital LLC TRC boosted its holdings in Novavax by 437.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 37,335 shares of the biopharmaceutical company's stock valued at $235,000 after purchasing an additional 30,386 shares in the last quarter. Finally, E Fund Management Co. Ltd. boosted its holdings in Novavax by 9.0% in the 2nd quarter. E Fund Management Co. Ltd. now owns 28,280 shares of the biopharmaceutical company's stock valued at $178,000 after purchasing an additional 2,326 shares in the last quarter. Hedge funds and other institutional investors own 53.04% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对该股票的持仓进行了调整。Thrivent Financial for Lutherans 在第二季度购买了诺瓦瓦克斯的新股份，价值约为 132.1 万美元。怀俄明州购买了诺瓦瓦克斯的新股份，价值约为 52,000 美元。Headlands Technologies LLC 在第二季度购买了诺瓦瓦克斯的新股份，价值约为 90.3 万美元。Tower Research Capital LLC TRC 在第二季度将其在诺瓦瓦克斯的持股增加了 437.3%。Tower Research Capital LLC TRC 现在拥有诺瓦瓦克斯生物制药公司价值 23.5 万美元的 37,335 股股票，此前在上个季度又购买了 30,386 股。最后，E Fund Management Co. Ltd.在第二季度将其在诺瓦瓦克斯的持股增加了 9.0%。E Fund Management Co. Ltd.现在拥有诺瓦瓦克斯生物制药公司价值 17.8 万美元的 28,280 股股票，此前在上个季度又购买了 2,326 股。对冲基金和其他机构投资者持有该公司 53.04% 的股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research analysts have recently commented on the company. Bank of America restated an &#34;underperform&#34; rating and set a $7.00 price target (down from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. HC Wainwright raised their price target on Novavax from $10.00 to $11.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, October 23rd. Cantor Fitzgerald began coverage on Novavax in a research report on Friday, October 24th. They set an &#34;overweight&#34; rating and a $18.00 price target for the company. Finally, Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of Novavax in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of &#34;Hold&#34; and an average target price of $11.33.</p>
<div class="lb-trans"><p>几位研究分析师最近对该公司发表了评论。美国银行在 8 月 20 日的研究报告中重申了 “表现不佳” 的评级，并将诺瓦瓦克斯的目标价从$9.00 下调至$7.00。HC Wainwright 在 10 月 23 日的研究报告中将诺瓦瓦克斯的目标价从$10.00 上调至$11.00，并给予该股票 “买入” 评级。Cantor Fitzgerald 在 10 月 24 日的研究报告中开始覆盖诺瓦瓦克斯，设定了 “增持” 评级和$18.00 的目标价。最后，Weiss Ratings 在 10 月 8 日的报告中重申了诺瓦瓦克斯的 “卖出（d+）” 评级。四位分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，四位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为$11.33。</p>
</div><ul>
<li>Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna 在第二季度财报后下跌，但能否因短期挤压而反弹？</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on NVAX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 NVAX 的最新研究报告</strong></p>
</div><h2>About Novavax</h2>
<div class="lb-trans"><h2>关于诺瓦瓦克斯</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.</p>
<div class="lb-trans"><p>诺瓦瓦克斯公司是一家生物技术公司，致力于通过发现、开发和商业化疫苗来改善健康，以保护人们免受严重传染病的侵害。它提供的疫苗平台结合了重组蛋白方法、纳米颗粒技术和其专利的 Matrix-M 佐剂，以增强免疫反应。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Novavax</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>Comfort Systems Is the AI Data Center Stock Beating NVDA, AVGO, &amp; AMD</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Cameco's $80 Billion U.S. Nuclear Deal Changes Everything</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>NU Stock: U.S. Bank License May Be the Next Growth Catalyst</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非诺瓦瓦克斯</li>
<li>复利及其在投资中的重要性</li>
<li>Comfort Systems 是击败 NVDA、AVGO 和 AMD 的 AI 数据中心股票</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>Cameco 的 800 亿美元美国核能交易改变一切</li>
<li>万亿美元市值的意义超越数字</li>
<li>NU 股票：美国银行许可证可能是下一个增长催化剂</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlZBWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=NVAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novavax Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在诺瓦瓦克斯吗？</h2>
</div><p>Before you consider Novavax, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑诺瓦瓦克斯之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而诺瓦瓦克斯并不在名单上。</p>
</div><p>While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺瓦瓦克斯目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

诺瓦瓦克斯医药（NVAX）将于周四公布财报